PA8814801A1 - Triazolopiridazinas como inhibidores de par1, su preparación y su uso como medicamentos - Google Patents
Triazolopiridazinas como inhibidores de par1, su preparación y su uso como medicamentosInfo
- Publication number
- PA8814801A1 PA8814801A1 PA20098814801A PA8814801A PA8814801A1 PA 8814801 A1 PA8814801 A1 PA 8814801A1 PA 20098814801 A PA20098814801 A PA 20098814801A PA 8814801 A PA8814801 A PA 8814801A PA 8814801 A1 PA8814801 A1 PA 8814801A1
- Authority
- PA
- Panama
- Prior art keywords
- medications
- preparation
- triazolopiridazinas
- par1 inhibitors
- par1
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
LA INVENCIÓN SE REFIERE A COMPUESTOS DE FÓRMULA I CON ACTIVIDAD ANTTROMBÓTICA,QUE INHIBEN ESPECIALMENTE EL RECEPTOR 1 ACTIVADO POR PROTEASA,A MÉTODOS PARA SU PREPARACIÓN Y A SU USO COMO MEDICAMENTOS.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08290112 | 2008-02-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
PA8814801A1 true PA8814801A1 (es) | 2009-09-17 |
Family
ID=39539711
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PA20098814801A PA8814801A1 (es) | 2008-02-05 | 2009-02-03 | Triazolopiridazinas como inhibidores de par1, su preparación y su uso como medicamentos |
Country Status (32)
Country | Link |
---|---|
US (2) | US8076336B2 (es) |
EP (1) | EP2240487B1 (es) |
JP (1) | JP5526040B2 (es) |
KR (1) | KR20100114514A (es) |
CN (1) | CN101981034B (es) |
AR (1) | AR070410A1 (es) |
AT (1) | ATE537172T1 (es) |
AU (1) | AU2009211887B2 (es) |
BR (1) | BRPI0907486A2 (es) |
CA (1) | CA2713550C (es) |
CL (1) | CL2009000236A1 (es) |
CO (1) | CO6260083A2 (es) |
CY (1) | CY1113228T1 (es) |
DK (1) | DK2240487T3 (es) |
ES (1) | ES2379447T3 (es) |
HK (1) | HK1149011A1 (es) |
HR (1) | HRP20120230T1 (es) |
IL (1) | IL207205A0 (es) |
MA (1) | MA32061B1 (es) |
MX (1) | MX2010008490A (es) |
MY (1) | MY152040A (es) |
NZ (1) | NZ587141A (es) |
PA (1) | PA8814801A1 (es) |
PE (1) | PE20091455A1 (es) |
PL (1) | PL2240487T3 (es) |
PT (1) | PT2240487E (es) |
RS (1) | RS52264B (es) |
RU (1) | RU2499797C2 (es) |
SI (1) | SI2240487T1 (es) |
TW (1) | TW200946532A (es) |
WO (1) | WO2009097970A1 (es) |
ZA (1) | ZA201004467B (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8481538B2 (en) * | 2006-09-18 | 2013-07-09 | Vertex Pharmaceuticals Incorporated | Heterocyclic inhibitors of c-Met and uses thereof |
JP5577259B2 (ja) * | 2008-02-05 | 2014-08-20 | サノフイ | Par1阻害剤としてのトリアゾリウム塩、その製造、及び薬剤としての使用 |
US8673890B2 (en) | 2009-10-29 | 2014-03-18 | Janssen Pharmaceutica Nv | 2,3-dihydro-1H-isoindol-1-imine derivatives useful as thrombin PAR-1 receptor antagonist |
CN113993852A (zh) * | 2019-06-19 | 2022-01-28 | Nmd制药股份公司 | 用于制备ClC-1氯离子通道抑制剂的方法 |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4578464A (en) | 1983-11-22 | 1986-03-25 | Merrell Dow Pharmaceuticals Inc. | 6-Hydroxyalkylamino-8-methyl-1,2,4-triazolo-[4,3-b]pyridazine and related compounds |
CA2198019A1 (en) * | 1994-09-16 | 1996-03-21 | Takeda Chemical Industries, Ltd. | Triazolopyridazines process and intermediates for their preparation and their use as medicaments |
US6063847A (en) | 1997-11-25 | 2000-05-16 | Schering Corporation | Thrombin receptor antagonists |
US7488742B2 (en) | 2000-06-15 | 2009-02-10 | Schering Corporation | Thrombin receptor antagonists |
CA2446924C (en) * | 2001-04-19 | 2011-02-08 | Eisai Co., Ltd. | 2-iminopyrrolidine derivatives |
CA2448509A1 (en) | 2001-05-25 | 2002-12-05 | Mochida Pharmaceutical Co., Ltd. | 4-hydroxypiperidine derivatives having analgesic activity |
WO2003031442A1 (fr) | 2001-10-05 | 2003-04-17 | Takeda Chemical Industries, Ltd. | Composes heterocycliques, derives oxazole, procede permettant de les presenter et leur utilisation |
IL160918A0 (en) | 2001-10-18 | 2004-08-31 | Schering Corp | Himbacine analogues as thrombin receptor antagonists |
SG164279A1 (en) | 2002-04-16 | 2010-09-29 | Schering Corp | Tricyclic thrombin receptor antagonists |
AU2004218187C1 (en) | 2003-02-19 | 2011-04-07 | Eisai R&D Management Co., Ltd. | Methods for producing cyclic benzamidine derivatives |
TW200531688A (en) | 2004-03-05 | 2005-10-01 | Hoffmann La Roche | Novel pentafluorosulfanyl compounds, their manufacture and use as pharmaceutical agents |
EP1813282A4 (en) | 2004-11-09 | 2011-03-02 | Eisai R&D Man Co Ltd | MEANS FOR THE TREATMENT OF ANGIOSPASM IN SUBARACHO-OAL BLOODING WITH THROMBIN RECEPTOR ANTAGONIST AS AN ACTIVE AGENT |
RS55630B1 (sr) * | 2005-12-21 | 2017-06-30 | Janssen Pharmaceutica Nv | Triazolopiridazini kao modulatori tirozin kinaze |
DE102006025318A1 (de) * | 2006-05-31 | 2007-12-06 | Bayer Healthcare Ag | Dihydro-pyrrolopyridin-, Dihydro-pyrrolopyridazin- und Dihydro-pyrrolopyrimidin-Derivate und ihre Verwendung |
DE102006036023A1 (de) * | 2006-08-02 | 2008-02-07 | Sanofi-Aventis | Imino-imidazo-pyridinderivate mit antithrombotischer Aktivität |
BRPI0907700A2 (pt) | 2008-02-05 | 2015-07-21 | Sanofi Aventis | Imidazopiridazinas como inibidores par1, produção das mesmas e uso como medicamentos |
JP5577259B2 (ja) | 2008-02-05 | 2014-08-20 | サノフイ | Par1阻害剤としてのトリアゾリウム塩、その製造、及び薬剤としての使用 |
JP2011511018A (ja) | 2008-02-05 | 2011-04-07 | サノフィ−アベンティス | Par1阻害剤としてのsf5誘導体、その製造、及び薬剤としての使用 |
US8324241B2 (en) | 2008-04-11 | 2012-12-04 | Bristol-Myers Squibb Company | Triazolo compounds useful as DGAT1 inhibitors |
US8394823B2 (en) | 2008-04-11 | 2013-03-12 | Bristol-Myers Squibb Company | Triazolopyridine compounds useful as DGAT1 inhibitors |
-
2009
- 2009-01-23 JP JP2010545378A patent/JP5526040B2/ja not_active Expired - Fee Related
- 2009-01-23 WO PCT/EP2009/000406 patent/WO2009097970A1/de active Application Filing
- 2009-01-23 EP EP09708289A patent/EP2240487B1/de active Active
- 2009-01-23 CA CA2713550A patent/CA2713550C/en not_active Expired - Fee Related
- 2009-01-23 MY MYPI20103226 patent/MY152040A/en unknown
- 2009-01-23 AT AT09708289T patent/ATE537172T1/de active
- 2009-01-23 NZ NZ587141A patent/NZ587141A/en not_active IP Right Cessation
- 2009-01-23 ES ES09708289T patent/ES2379447T3/es active Active
- 2009-01-23 CN CN2009801115086A patent/CN101981034B/zh not_active Expired - Fee Related
- 2009-01-23 RS RS20120103A patent/RS52264B/en unknown
- 2009-01-23 KR KR1020107017452A patent/KR20100114514A/ko not_active Application Discontinuation
- 2009-01-23 AU AU2009211887A patent/AU2009211887B2/en not_active Ceased
- 2009-01-23 PL PL09708289T patent/PL2240487T3/pl unknown
- 2009-01-23 DK DK09708289.5T patent/DK2240487T3/da active
- 2009-01-23 PT PT09708289T patent/PT2240487E/pt unknown
- 2009-01-23 BR BRPI0907486-4A patent/BRPI0907486A2/pt not_active IP Right Cessation
- 2009-01-23 RU RU2010136957/04A patent/RU2499797C2/ru not_active IP Right Cessation
- 2009-01-23 MX MX2010008490A patent/MX2010008490A/es active IP Right Grant
- 2009-01-23 SI SI200930192T patent/SI2240487T1/sl unknown
- 2009-02-03 TW TW098103334A patent/TW200946532A/zh unknown
- 2009-02-03 PE PE2009000154A patent/PE20091455A1/es not_active Application Discontinuation
- 2009-02-03 AR ARP090100348A patent/AR070410A1/es not_active Application Discontinuation
- 2009-02-03 PA PA20098814801A patent/PA8814801A1/es unknown
- 2009-02-03 CL CL2009000236A patent/CL2009000236A1/es unknown
-
2010
- 2010-06-24 ZA ZA2010/04467A patent/ZA201004467B/en unknown
- 2010-07-25 IL IL207205A patent/IL207205A0/en unknown
- 2010-08-04 MA MA33059A patent/MA32061B1/fr unknown
- 2010-08-04 CO CO10095026A patent/CO6260083A2/es active IP Right Grant
- 2010-08-05 US US12/851,189 patent/US8076336B2/en not_active Expired - Fee Related
-
2011
- 2011-03-30 HK HK11103239.2A patent/HK1149011A1/xx not_active IP Right Cessation
- 2011-09-23 US US13/243,118 patent/US9079906B2/en not_active Expired - Fee Related
-
2012
- 2012-03-13 HR HR20120230T patent/HRP20120230T1/hr unknown
- 2012-03-14 CY CY20121100256T patent/CY1113228T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2007002682A1 (es) | Compuestos derivados de 4-metilpiridopirimidinona; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar el crecimiento anormal de celulas, como cancer. | |
UY39963A (es) | Composiciones herbicidas a base de carbamoíltriazolinona y métodos de uso | |
BRPI0921063B8 (pt) | composto, e, composição agonística para receptor de melanocortina | |
CO6321189A2 (es) | Compuestos de tiazol y oxazol de bencen-sulfonamida | |
PA8827101A1 (es) | Derivados de indazoles sustituidos con fenilo o piridinilo | |
CL2013002171A1 (es) | Composicion fungicida y bactericida que comprende compuestos organicos volatiles de origen natural; uso de la composición. | |
CR10309A (es) | "compuestos y composiciones como inhibidores de la actividad del receptor canabinoide 1" | |
HN2008001723A (es) | Nitrilos espirociclicos como inhibidores de proteasa | |
CL2008003690A1 (es) | Compuestos derivados de amonobenzamida; composicion farmceutica que comprende los compuestos; y uso para controlar parasitos. | |
CL2012000921A1 (es) | Compuestos derivados de espiropiperidina-metilbenciloxifenil, activadores del receptor rpg-40; composicion farmaceutica que los comprende; y uso del compuesto para tratar diabetes. | |
SV2010003593A (es) | Nuevos herbicidas | |
CL2014003191A1 (es) | Compuestos que inhiben la actividad de catecol o -metiltransferasa; su uso contra el parkinson. | |
GT200900315A (es) | Inhibición de arni de expresión de alfa-enac | |
NI201000035A (es) | Derivados de azaciclilisoquinolinona e isoindolinona como antagonistas de histamina-3 | |
CL2007002519A1 (es) | Compuestos derivados de aminopiridina, inhibidores selectivo sobre aurora a; composicion farmaceutica que comprende a dichos compuestos; combinacion farmaceutica que comprende a dichos compuestos, utiles para inhibir el crecimiento de celulas tumoral | |
CL2008002041A1 (es) | Compuestos derivados de piperidina; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar ansiedad. | |
GT201000047A (es) | Mejoras en compuestos organicos o relacionadas con los mismos | |
NI201000036A (es) | Derivados de isoquinolinilo e isoindolinilo como antagonistas de histamina-3 | |
UY33655A (es) | Co-cristales y sales de inhibidores de ccr30 | |
UY32734A (es) | Compuestos agonistas del receptor esfingosina 1-fosfato | |
CL2009000904A1 (es) | Compuestos derivados de ciclohexil sulfonamidas que tienen actividad antagonista en el receptor npy y5, composicion farmaceutica y formulacion farmaceutica que los comprende. | |
CL2008000090A1 (es) | Compuestos derivados de piridina; composicion farmaceutica que comprende a dichos compuestos; y su uso como inhibidores del receptor p2y 12 para tratar un trastorno de agragacion de plaquetas. | |
PA8814801A1 (es) | Triazolopiridazinas como inhibidores de par1, su preparación y su uso como medicamentos | |
CL2008000093A1 (es) | Compuestos derivados de piridina, inhibidores de p2y12; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de un desorden de agregacion plaquetaria. | |
ATE533477T1 (de) | Pharmazeutische zusammensetzungen enthaltend irbesartan |